Treatment recommendations for chronic hepatitis B

Tong, Myron J.; Hsien, Carlos; Hsu, Leeyen; Sun, Hai-En; Blatt, Lawrence M.

doi:10.1002/hep.22476

Cited by 84 publications

(97 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tong et al [6] applied the four criteria (European Association for the Study of the Liver, a treatment algorithm by an independent panel of hepatologists in the United States, an Asian-Pacific consensus statement and the practice guidelines from the American Association for the study of liver disease) to treat 369 HBsAg-positive patients with antiviral therapy. Using these criteria for antiviral therapy as stated by the guidelines, only 20%-60% of hepatocellular carcinoma (HCC) patients and 27%-70% of patients who died of non-HCC were identified for antiviral therapy.…”

Section: To the Editormentioning

confidence: 99%

DNA-guided hepatitis B treatment: Viral load is insufficient with few exceptions

Jain¹

2009

WJG

View full text Add to dashboard Cite

In DNA-guided hepatitis B treatment, viral load is insufficient, and requires other viral markers for treatment of hepatitis B patients as in patients with acute exacerbation of chronic hepatitis B, end-stage renal disease on dialysis, human immunodeficiency virus co-infected patients. There are exceptions to this rule: a residual level hepatitis B virus (HBV) DNA at 24 wk predicts beneficial outcome and reduced resistance at 1 year. The genotypic viral resistance to antiviral agents and occult HBV infection can be determined by HBV-DNA levels.

show abstract

Section: To the Editormentioning

confidence: 99%

DNA-guided hepatitis B treatment: Viral load is insufficient with few exceptions

Jain¹

2009

WJG

View full text Add to dashboard Cite

show abstract

“…[6][7][8] Lamivudine and entecavir are the two drugs most extensively used to treat HBV carriers. Some retrospective and prospective studies have indicated that lamivudine and entecavir are both effective for controlling HBV reactivation in allo-HSCT recipients.…”

Section: Introductionmentioning

confidence: 99%

A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience

Shang

Wang

Sun

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

The aim of this study was to compare the efficacy of lamivudine vs entecavir in the prevention of hepatitis B virus (HBV) reactivation in HBV surface Ag (HBsAg)-positive patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 216 consecutive patients were enrolled and retrospectively reviewed. Of these patients, 119 received lamivudine and 97 received entecavir. The median treatment duration to complete virological response in patients with baseline HBV-DNA levels 410 5 copies/mL was 2.0 months in the entecavir group, significantly shorter than that of the lamivudine group. After a median follow-up of 24 months post transplantation, the cumulative incidence rates of HBV reactivation at 6, 12 and 24 months following transplantation were 3.0%, 7.0% and 24.0% in the lamivudine group, and 0%, 0% and 2.0% in the entecavir group, respectively. In addition, entecavir treatment was associated with lower cumulative incidence rates of severe hepatitis caused by HBV reactivation. Mutations leading to drug resistance were detected in 25 patients in the lamivudine group and in only one patient in the entecavir group. Our data indicate that compared with lamivudine, entecavir has more potent antiviral efficacy and may be a better choice for prophylaxis of HBV reactivation in HBsAg-positive allo-HSCT recipients.

show abstract

“…Most of the current treatment guidelines for CHB suggest that treatment is indicated in patients with HBV-DNA greater than 20,000 IU/MI for HBeAgpositive CHB and when HBV-DNA is greater than 2,000 IU/ML for HBeAg-negative CHB, together with evidence of active inflammation as reflected by elevated serum ALT or liver histology in the absence of other causes for liver disease [2,[15][16][17][18]. Treatment responders among CHB patients will have a reduction in the risk of progression to cirrhosis and HCC [15,16,19,20].…”

Section: Introductionmentioning

confidence: 99%

Chronic hepatitis B infection in a hepatology clinic at a university hospital in Jeddah

Fallatah

Akbar

2010

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The outcome of chronic hepatitis B (CHB) infection in a cohort of CHB patients at the hepatology clinics of King Abdul Aziz University Hospital in Jeddah was studied. Methodology: The results of a complete blood count, prothrombin time, liver function test and hepatitis B virus polymerase chain reaction (HBV-PCR) performed over the previous two to five years of follow-up were reviewed. Results of abdominal ultrasound performed within the last year and the data on the treatment type, duration and resistance were also obtained. Results: The majority of the 109 patients studied were Hepatitis B e antigen (HBeAg-negative; 87.2%). Male patients had higher serum ALT values compared to females at follow-up. HBeAg-positive patients had higher HBV-PCR levels at diagnosis compared to HBeAgnegative patients. Patients below 40 years of age had higher HBV-PCR compared to those above 40 years. Ultrasound showed liver cirrhosis in 11% of patients. Cirrhotic patients had higher GGT levels compared to non cirrhotic patients. Drug resistance developed in 25% of the 20 Lamivudine-treated patients. The mean duration of treatment was 2.5 ± .47 years. Conclusion: CHB was predominantly HBeAg negative, with a benign long-term outcome in most patients. Therapy may need to be individualized for patients with high risk of progression.

show abstract

Treatment recommendations for chronic hepatitis B

Cited by 84 publications

References 33 publications

DNA-guided hepatitis B treatment: Viral load is insufficient with few exceptions

DNA-guided hepatitis B treatment: Viral load is insufficient with few exceptions

A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience

Chronic hepatitis B infection in a hepatology clinic at a university hospital in Jeddah

Contact Info

Product

Resources

About